HIV-1 Infection, HIV Infection, Infection, Human Immunodeficiency Virus I
Conditions
Keywords
HIV, HLA-B*5701, prevalence, Treatment Experienced, Treatment Naive
Brief summary
This study is a cross-sectional observational study to evaluate the prevalence of HLA-B\*5701 in the European area and in major European ethnotypes. Any HIV-1 infected patient will be eligible for this study including treatment naïve and experienced patients, as well as patients previously tested for HLA-B\*5701. Patients will be approached during a standard clinic visit, and will be consented prior to any study specific procedure. They will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B\*5701 status by local and central laboratories. In selected sites patients may be asked to provide an additional blood sample. This sample will be used to develop and validate different methodologies for assessing HLA-B\*5701 status.
Interventions
PROCEDURECheek cells sample
Cheek cells sample
PROCEDUREBlood sample
Blood sample
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1 infected patients over the age of 18 years * Patient is willing and able to understand and provide written informed consent
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of HLA-B*5701 in European HIV-1 population | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of HLA-B*5701 in major European ethnotypes | — |
Countries
Finland, Ireland, Netherlands, Portugal, Switzerland
Outcome results
None listed